Faruqi and Faruqui, LLP Logo
Share this page

Intercept Pharmaceuticals Inc. (ICPT)

NASDAQ: ICPT

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Intercept Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) of the November 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Intercept stock or options between May 31, 2016 and September 20, 2017 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Intercept securities between May 31, 2016 and September 20, 2017 (the “Class Period”).  The case, DeSmet v. Intercept Pharmaceuticals, Inc. et al., No. 1:17-cv-07371 was filed on September 27, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company’s lead product candidate Ocaliva, a bile acid analog for the treatment of primary biliary cholangitis (“PBC”), entailed undisclosed safety risks, including death, to patients suffering from PBC; and (ii) as a result, Intercept's public statements were materially false and misleading at all relevant times.


Specifically, on September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva, advising them that the drug has been tied to liver injuries and death among patients suffering from PBC.  On this news, Intercept’s share price fell from $113.48 per share on September 11, 2017 to a closing price of $98.12 on September 12, 2017—a $15.36 or a 13.54% drop.

Then, on September 21, 2017, the U.S. Food and Drug Administration (“FDA”) issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug.  On this news, Intercept’s share price fell from $98.12 per share on September 20, 2017 to a closing price of $73.70 on September 21, 2017—a $24.42 or a 24.89% drop.

 

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Intercept Pharmaceuticals Inc. (ICPT)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 09/27/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.